The process of myocardial inJury associated with oxidative cell damage is known to be related to an enhanced production of free radicals [l]. The therapeutic potential of radical scavengers has however been debated, since the damaging properties of oxygen radicals is more directed towards the formation of secondary products, including more long lasting radical species derived from superoxide anions. In that respect the effect of chain breaking antioxidants, such as a-tocopherol, with possibilities to protect against lipid radical formation and lipid peroxidation is relevant [2,31.
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Several f a c t o r s a r e involved in t h e development of irreversible cell damage by hypoxia a n d reoxygenation of myocytes. Hypoxia is associated with an increased degradation of phospholipids and an increased accumulation of free fatty acids. These factors a r e both coupled to cell damage which follows reoxygenation of myocytes, since polyunsaturated fatty acids, which a r e highly susceptible to oxidative destruction, act as initiators of lipid peroxidation.
Other protective effects of a-tocopherol, beside its chain breaking antioxidative effect, have been suggested such as its membrane stabilizing properties [4, 5] . This effect may also be protective in myocardial cell damage.
The present study was performed in order to investigate the protective effect of antioxidants on the release of the cytosolic enzyme, lactate dehydrogenase (LD) following hypoxiareoxygenation of neonatal ventricular myocytes. As a complement to LD-release, lipid peroxidation was determined by analyzing thiobarbituric acid reactive substances (TBARS) in the medium. The antioxidative potency of each compound was estimated in Fe2+/ascorbate activated liposomes analyzing TBARS [6] which was compared to the effect on LD-release.
The myocytes 1.5-1.8 celld35 mm dish, were cultured from 6-7 days old rats in F10 medium with 10% fetal bovine serum and antioxidant for 6 days. The used antioxidants were a-tocopherol, p-carotene, nordihydroguairetic acid (NDGA) and butylated hydroxy toluene (BHT). The myocytes were subjected to 1 hour of hypoxia and 4 hours reoxygenation in specially designed culture chambers. Hypoxia was induced by argon which was blown into the medium and by nitrogen, 95% N2, 5 % C02, which was gassed over the cells, p02=1.2%. Reoxygenation, 95% 02, 5 % C02, was performed during 4 hours.
The tested antioxidants significantly inhibited reoxygenation induced LD-release (Fig 1) .
The cell protective effect was not related to the antioxidative potency in the liposome system. In that case a-tocopherol and pcarotene showed a better protection against LD-release while NDGA and BHT were less protective (Table 1) . When the effect on a-tocopherol on TBARS formation and on LD-release were compared, the reduction in LD-release in the presence of 10 pM a-tocopherol was paralleled by a decrease in TBARS (Fig 2) . The presented data show that ventricular myocytes can be used to study reoxygenation induced cell damage. In this system we found that several antioxidants protect against LD-cell leakage. However, their protective effect was not directly related to their capacity to inhibit lipid peroxidation. Other effects as membrane stabilization may play a role in the myocyte system.
T h e p e r o x i d a t i o n of m y o c a r d i a l cell m e m b r a n e phospholipids may be protected by chain breaking antioxidants. However, i t r e m a i n t o b e p r o v e n if a -t o c o p h e r o l c a n therapeutically be used against coronary heart failure.
